Get the Stockscreener App
4.60
1.71%
-0.08
Scisparc Ltd stock is traded at $4.60, with a volume of 4,272.
It is down -1.71% in the last 24 hours and down -9.38% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$4.68
Open:
$4.6265
24h Volume:
4,272
Relative Volume:
0.02
Market Cap:
$2.60M
Revenue:
$927.00K
Net Income/Loss:
$-13.21M
P/E Ratio:
-0.0218
EPS:
-210.8843
Net Cash Flow:
$-4.77M
1W Performance:
-2.75%
1M Performance:
-9.38%
6M Performance:
-89.28%
1Y Performance:
+53.86%
1-Day Range:
$4.4719
$4.6265
1-Week Range:
$4.12
$4.68
52-Week Range:
$2.034
$80.10
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
4.60 | 2.65M | 927.00K | -13.21M | -4.77M | -210.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.93 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
730.56 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
680.36 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.19 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
281.95 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Scisparc Ltd Stock (SPRC) Latest News
SPRC SEC FilingsScisparc 10-K, 10-Q, 8-K Forms - Stock Titan
SciSparc (SPRC) director discloses shares, options and RSU awards - Stock Titan
SciSparc (SPRC) director reports initial share and option holdings - Stock Titan
SciSparc (SPRC) director Revach Moshe discloses initial share and RSU holdings - Stock Titan
SciSparc (SPRC) CEO Adler Oz details share, option and RSU holdings - Stock Titan
SciSparc (SPRC) director Weiss Amitay details equity holdings - Stock Titan
SciSparc (SPRC) director Vider Lior details shares, options and RSUs - Stock Titan
SciSparc (SPRC) CTO details 5,528 Ordinary Shares and option holdings on Form 3 - Stock Titan
SciSparc (SPRC) director reports 3,651-share stake and RSU grants - Stock Titan
Sentiment Watch: Can SciSparc Ltd stock outperform in a bear marketRecession Risk & Expert Verified Stock Movement Alerts - baoquankhu1.vn
SciSparc stock rallies after AutoMax files motion on pending merger - MSN
Buyout Rumor: Is SciSparc Ltd impacted by rising ratesMarket Performance Report & Low Drawdown Investment Ideas - baoquankhu1.vn
SciSparc subsidiary files patent for depression treatment By Investing.com - Investing.com India
[SCHEDULE 13G] SciSparc Ltd. Passive Investment Disclosure (>5%) - Stock Titan
SciSparc’s NeuroThera-Backed Collaboration Spurs New Depression Therapy Patent Filing - TipRanks
SciSparc (NASDAQ: SPRC) collaboration advances MEAI-PEA depression patent bid - Stock Titan
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - Bitget
SciSparc subsidiary files patent for depression treatment - Investing.com
SciSparc Ltd. Reports NeuroThera Labs' Patent Application for Innovative Depression Treatment Combining MEAI and PEA - Quiver Quantitative
Non-hallucinogenic depression combo MEAI-PEA seeks Hong Kong patent - Stock Titan
SciSparc Subsidiary NeuroThera to Take Majority Stake in Quantum Trials Firm CliniQuantum - TipRanks
SciSparc (Nasdaq: SPRC) unit to acquire 54% of CliniQuantum and lose NeuroThera control - Stock Titan
SciSparc’s Neurothera Labs announces publication of international patent - TipRanks
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Bitget
SciSparc Ltd. Advances Collaboration with NeuroThera Labs Inc. and Clearmind Medicine Inc. for Novel Combination Therapy Targeting Obesity and MASLD. - Quiver Quantitative
SciSparc: $9.46 Million NeuroThera Deal To Acquire Majority Stake In Quantum Clinical Trials Firm CliniQuantum - Pulse 2.0
SciSparc, Subsidiary NeuroThera Labs Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails - marketscreener.com
SPRC Stock Price, Quote & Chart | SCISPARC LTD (NASDAQ:SPRC) - ChartMill
NeuroThera to acquire 54% stake in quantum tech firm CliniQ By Investing.com - Investing.com South Africa
SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails - Bitget
SciSparc says Neurothera Labs agrees to acquire majority stake in CliniQuantum - TipRanks
SciSparc Ltd. Subsidiary NeuroThera Labs Inc. Enters Share Purchase Agreement to Acquire Majority Stake in CliniQuantum Ltd. - Quiver Quantitative
SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive - GlobeNewswire
Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd. - TheNewswire
Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd. (2026-03-10) - Seeking Alpha
SciSparc Ltd. (SPRC) Schedule 13G/A amendment shows holder ≤5% - Stock Titan
Can SciSparc Ltd. stock resist market sell offsJuly 2025 Update & Accurate Trade Setup Notifications - Naître et grandir
Aug Reactions: What is the implied volatility of SciSparc LtdEarnings Summary Report & Fast Gain Stock Trading Tips - baoquankhu1.vn
Analyst Upgrade: Whats the beta of SciSparc Ltd stockPortfolio Update Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
SciSparc announces publication of Japanese patent application - MSN
SciSparc announces 1-for-9 reverse share split - Yahoo Finance
SciSparc to implement 1-for-9 reverse stock split Wednesday - Investing.com India
SciSparc to Enact 1-for-9 Reverse Share Split as Outstanding Shares Shrink - The Globe and Mail
SciSparc to implement 1-for-9 reverse stock split Wednesday By Investing.com - Investing.com Canada
SciSparc Falls 12% After Announcing 1-for-9 Reverse Share Split - Nasdaq
SciSparc Announces 1-for-9 Reverse Share Split - The Manila Times
SciSparc (NASDAQ: SPRC) to implement 1-for-9 reverse share split - Stock Titan
SciSparc Amends $10 Million Note Deal, Issues $2 Million Initial Convertible Note - TipRanks
SciSparc (SPRC) arranges up to $10M discounted convertible note deal - Stock Titan
Is SciSparc Ltd. stock safe for conservative investorsShare Buyback & Target Return Focused Stock Picks - mfd.ru
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):